Depomed (NASDAQ: DEPO) has recently received a number of price target changes and ratings updates: 12/3/2015 – Depomed is now covered by analysts at Morgan Stanley. They set an “equal weight” rating and a $21.00 price target on the stock. 11/30/2015 – Depomed had its “buy” rating reaffirmed by analysts at Roth Capital. They now […]
